{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:03:18Z","timestamp":1790697798890,"version":"4.1.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00296-019-04467-6","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T04:56:47Z","timestamp":1572843407000},"page":"191-205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Biologic therapy in the idiopathic inflammatory myopathies"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1122-3384","authenticated-orcid":false,"given":"Thomas","family":"Khoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8142-9532","authenticated-orcid":false,"given":"Vidya","family":"Limaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,4]]},"reference":[{"issue":"3","key":"4467_CR1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11926-012-0249-3","volume":"14","author":"I Marie","year":"2012","unstructured":"Marie I (2012) Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep 14(3):275\u2013285. \nhttps:\/\/doi.org\/10.1007\/s11926-012-0249-3","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"4467_CR2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jbspin.2006.11.013","volume":"74","author":"D Wendling","year":"2007","unstructured":"Wendling D (2007) Biologics in the treatment of primary inflammatory myositis. Jt Bone Spine 74(4):316\u2013318. \nhttps:\/\/doi.org\/10.1016\/j.jbspin.2006.11.013","journal-title":"Jt Bone Spine"},{"issue":"6","key":"4467_CR3","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/BOR.0000000000000109","volume":"26","author":"IE Lundberg","year":"2014","unstructured":"Lundberg IE, Vencovsky J, Alexanderson H (2014) Therapy of myositis: biological and physical. Curr Opin Rheumatol 26(6):704\u2013711. \nhttps:\/\/doi.org\/10.1097\/BOR.0000000000000109","journal-title":"Curr Opin Rheumatol"},{"issue":"9388","key":"4467_CR4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362(9388):971\u2013982. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(03)14368-1","journal-title":"Lancet"},{"issue":"10","key":"4467_CR5","first-page":"2230","volume":"28","author":"I Marie","year":"2001","unstructured":"Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, Courtois H (2001) Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol 28(10):2230\u20132237","journal-title":"J Rheumatol"},{"issue":"6","key":"4467_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/BOR.0000000000000326","volume":"28","author":"N Pipitone","year":"2016","unstructured":"Pipitone N (2016) Value of MRI in diagnostics and evaluation of myositis. Curr Opin Rheumatol 28(6):625\u2013630. \nhttps:\/\/doi.org\/10.1097\/BOR.0000000000000326","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"4467_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","volume":"52","author":"M Satoh","year":"2017","unstructured":"Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EK (2017) A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 52(1):1\u201319. \nhttps:\/\/doi.org\/10.1007\/s12016-015-8510-y","journal-title":"Clin Rev Allergy Immunol"},{"key":"4467_CR8","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.bbadis.2014.05.034","volume":"4","author":"YB Luo","year":"2015","unstructured":"Luo YB, Mastaglia FL (2015) Dermatomyositis, polymyositis and immune-mediated necrotising myopathies. Biochim Biophys Acta 1852 4:622\u2013632. \nhttps:\/\/doi.org\/10.1016\/j.bbadis.2014.05.034","journal-title":"Biochim Biophys Acta 1852"},{"issue":"1","key":"4467_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.berh.2016.04.007","volume":"30","author":"J Tieu","year":"2016","unstructured":"Tieu J, Lundberg IE, Limaye V (2016) Idiopathic inflammatory myositis. Best Pract Res Clin Rheumatol 30(1):149\u2013168. \nhttps:\/\/doi.org\/10.1016\/j.berh.2016.04.007","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"3","key":"4467_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s11926-011-0176-8","volume":"13","author":"E Katzap","year":"2011","unstructured":"Katzap E, Barilla-LaBarca ML, Marder G (2011) Antisynthetase syndrome. Curr Rheumatol Rep 13(3):175\u2013181. \nhttps:\/\/doi.org\/10.1007\/s11926-011-0176-8","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"4467_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/08916930600622645","volume":"39","author":"A Ghirardello","year":"2006","unstructured":"Ghirardello A, Zampieri S, Tarricone E, Iaccarino L, Bendo R, Briani C, Rondinone R, Sarzi-Puttini P, Todesco S, Doria A (2006) Clinical implications of autoantibody screening in patients with autoimmune myositis. Autoimmunity 39(3):217\u2013221. \nhttps:\/\/doi.org\/10.1080\/08916930600622645","journal-title":"Autoimmunity"},{"issue":"1","key":"4467_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/ene.13357","volume":"25","author":"KEN Clark","year":"2018","unstructured":"Clark KEN, Isenberg DA (2018) A review of inflammatory idiopathic myopathy focusing on polymyositis. Eur J Neurol 25(1):13\u201323. \nhttps:\/\/doi.org\/10.1111\/ene.13357","journal-title":"Eur J Neurol"},{"issue":"4 Pt 2","key":"4467_CR13","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1016\/j.lpm.2010.12.013","volume":"40","author":"RK Gherardi","year":"2011","unstructured":"Gherardi RK (2011) Pathogenic aspects of dermatomyositis, polymyositis and overlap myositis. Presse Med 40(4 Pt 2):e209\u2013218. \nhttps:\/\/doi.org\/10.1016\/j.lpm.2010.12.013","journal-title":"Presse Med"},{"issue":"6","key":"4467_CR14","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1212\/01.wnl.0000277527.69388.fe","volume":"70","author":"N Chahin","year":"2008","unstructured":"Chahin N, Engel AG (2008) Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 70(6):418\u2013424. \nhttps:\/\/doi.org\/10.1212\/01.wnl.0000277527.69388.fe","journal-title":"Neurology"},{"issue":"5","key":"4467_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41584-019-0186-x","volume":"15","author":"SA Greenberg","year":"2019","unstructured":"Greenberg SA (2019) Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol 15(5):257\u2013272. \nhttps:\/\/doi.org\/10.1038\/s41584-019-0186-x","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"4467_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11926-015-0548-6","volume":"17","author":"P Basharat","year":"2015","unstructured":"Basharat P, Christopher-Stine L (2015) Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep 17(12):72. \nhttps:\/\/doi.org\/10.1007\/s11926-015-0548-6","journal-title":"Curr Rheumatol Rep"},{"issue":"Suppl 1","key":"4467_CR17","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/ar2885","volume":"12","author":"SA Greenberg","year":"2010","unstructured":"Greenberg SA (2010) Type 1 interferons and myositis. Arthritis Res Ther 12(Suppl 1):S4. \nhttps:\/\/doi.org\/10.1186\/ar2885","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"4467_CR18","doi-asserted-by":"publisher","first-page":"e65362","DOI":"10.1371\/journal.pone.0065362","volume":"8","author":"S Franzi","year":"2013","unstructured":"Franzi S, Salajegheh M, Nazareno R, Greenberg SA (2013) Type 1 interferons inhibit myotube formation independently of upregulation of interferon-stimulated gene 15. PLoS ONE 8(6):e65362. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0065362","journal-title":"PLoS ONE"},{"issue":"6","key":"4467_CR19","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/brain\/awy105","volume":"141","author":"L Ladislau","year":"2018","unstructured":"Ladislau L, Suarez-Calvet X, Toquet S, Landon-Cardinal O, Amelin D, Depp M, Rodero MP, Hathazi D, Duffy D, Bondet V, Preusse C, Bienvenu B, Rozenberg F, Roos A, Benjamim CF, Gallardo E, Illa I, Mouly V, Stenzel W, Butler-Browne G, Benveniste O, Allenbach Y (2018) JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain 141(6):1609\u20131621. \nhttps:\/\/doi.org\/10.1093\/brain\/awy105","journal-title":"Brain"},{"issue":"2","key":"4467_CR20","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1096\/fj.09-144782","volume":"24","author":"C Grundtman","year":"2010","unstructured":"Grundtman C, Bruton J, Yamada T, Ostberg T, Pisetsky DS, Harris HE, Andersson U, Lundberg IE, Westerblad H (2010) Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. FASEB J 24(2):570\u2013578. \nhttps:\/\/doi.org\/10.1096\/fj.09-144782","journal-title":"FASEB J"},{"issue":"5","key":"4467_CR21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s004010051165","volume":"99","author":"S Kuru","year":"2000","unstructured":"Kuru S, Inukai A, Liang Y, Doyu M, Takano A, Sobue G (2000) Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol 99(5):585\u2013588","journal-title":"Acta Neuropathol"},{"issue":"5","key":"4467_CR22","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/art.1780400514","volume":"40","author":"I Lundberg","year":"1997","unstructured":"Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L (1997) Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 40(5):865\u2013874. \nhttps:\/\/doi.org\/10.1002\/art.1780400514","journal-title":"Arthritis Rheum"},{"issue":"3","key":"4467_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.semarthrit.2006.07.003","volume":"36","author":"P Efthimiou","year":"2006","unstructured":"Efthimiou P (2006) Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiology and therapeutic implications. Semin Arthritis Rheum 36(3):168\u2013172. \nhttps:\/\/doi.org\/10.1016\/j.semarthrit.2006.07.003","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"4467_CR24","first-page":"887","volume":"26","author":"SM Sultan","year":"2008","unstructured":"Sultan SM, Ng KP, Edwards JC, Isenberg DA, Cambridge G (2008) Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol 26(5):887\u2013893","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"4467_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/joim.12451","volume":"280","author":"Z Betteridge","year":"2016","unstructured":"Betteridge Z, McHugh N (2016) Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 280(1):8\u201323. \nhttps:\/\/doi.org\/10.1111\/joim.12451","journal-title":"J Intern Med"},{"issue":"11","key":"4467_CR26","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1212\/01.wnl.0000187124.92826.20","volume":"65","author":"SA Greenberg","year":"2005","unstructured":"Greenberg SA, Bradshaw EM, Pinkus JL, Pinkus GS, Burleson T, Due B, Bregoli L, O'Connor KC, Amato AA (2005) Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 65(11):1782\u20131787. \nhttps:\/\/doi.org\/10.1212\/01.wnl.0000187124.92826.20","journal-title":"Neurology"},{"issue":"6","key":"4467_CR27","first-page":"896","volume":"31","author":"F Munoz-Beamud","year":"2013","unstructured":"Munoz-Beamud F, Isenberg DA (2013) Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies. Clin Exp Rheumatol 31(6):896\u2013903","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"4467_CR28","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/art.20849","volume":"52","author":"TD Levine","year":"2005","unstructured":"Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52(2):601\u2013607. \nhttps:\/\/doi.org\/10.1002\/art.20849","journal-title":"Arthritis Rheum"},{"issue":"3","key":"4467_CR29","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1111\/j.1445-5994.2011.02702.x","volume":"42","author":"V Limaye","year":"2012","unstructured":"Limaye V, Hissaria P, Liew CL, Koszyka B (2012) Efficacy of rituximab in refractory antisynthetase syndrome. Intern Med J 42(3):e4\u20137. \nhttps:\/\/doi.org\/10.1111\/j.1445-5994.2011.02702.x","journal-title":"Intern Med J"},{"issue":"5","key":"4467_CR30","first-page":"1021","volume":"33","author":"EH Noss","year":"2006","unstructured":"Noss EH, Hausner-Sypek DL, Weinblatt ME (2006) Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 33(5):1021\u20131026","journal-title":"J Rheumatol"},{"issue":"4","key":"4467_CR31","first-page":"615","volume":"37","author":"J Lopez","year":"2019","unstructured":"Lopez J, Merino L, Piris L, Herrera FS, Llorente I, Humbria A, Ortiz AM, Velasco T, Garcia-Vicuna R, Castaneda S, Gonzalez Alvaro I, Munoz-Calleja C (2019) Rituximab induces a lasting, non-cumulative remodelling of the B-cell compartment. Clin Exp Rheumatol 37(4):615\u2013622","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"4467_CR32","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/RHU.0b013e3181bb8e70","volume":"15","author":"S Majmudar","year":"2009","unstructured":"Majmudar S, Hall HA, Zimmermann B (2009) Treatment of adult inflammatory myositis with rituximab: an emerging therapy for refractory patients. J Clin Rheumatol 15(7):338\u2013340. \nhttps:\/\/doi.org\/10.1097\/RHU.0b013e3181bb8e70","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"4467_CR33","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE, Group RIMS (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65(2):314\u2013324. \nhttps:\/\/doi.org\/10.1002\/art.37754","journal-title":"Arthritis Rheum"},{"issue":"2","key":"4467_CR34","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/art.37758","volume":"65","author":"M de Visser","year":"2013","unstructured":"de Visser M (2013) The efficacy of rituximab in refractory myositis: the jury is still out. Arthritis Rheum 65(2):303\u2013306. \nhttps:\/\/doi.org\/10.1002\/art.37758","journal-title":"Arthritis Rheum"},{"key":"4467_CR35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/DNND.S19899","volume":"2","author":"R Aggarwal","year":"2012","unstructured":"Aggarwal R, Oddis CV (2012) Inclusion body myositis: therapeutic approaches. Degener Neurol Neuromuscul Dis 2:43\u201352. \nhttps:\/\/doi.org\/10.2147\/DNND.S19899","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"3","key":"4467_CR36","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/art.38270","volume":"66","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider LG, Harris-Love MO, Levesque MC, Group RIMS, Oddis CV (2014) Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 66(3):740\u2013749. \nhttps:\/\/doi.org\/10.1002\/art.38270","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"4467_CR37","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1093\/rheumatology\/key450","volume":"58","author":"V Leclair","year":"2019","unstructured":"Leclair V, Galindo-Feria AS, Dastmalchi M, Holmqvist M, Lundberg IE (2019) Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study. Rheumatology (Oxford) 58(7):1214\u20131220. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/key450","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"4467_CR38","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4081\/reumatismo.2018.1011","volume":"70","author":"S Barsotti","year":"2018","unstructured":"Barsotti S, Cioffi E, Tripoli A, Tavoni A, D'Ascanio A, Mosca M, Neri R (2018) The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature. Reumatismo 70(2):78\u201384. \nhttps:\/\/doi.org\/10.4081\/reumatismo.2018.1011","journal-title":"Reumatismo"},{"issue":"12","key":"4467_CR39","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/rheumatology\/ker088","volume":"50","author":"EA Mahler","year":"2011","unstructured":"Mahler EA, Blom M, Voermans NC, van Engelen BG, van Riel PL, Vonk MC (2011) Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford) 50(12):2206\u20132213. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/ker088","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"4467_CR40","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/ard.2005.045898","volume":"65","author":"L Brulhart","year":"2006","unstructured":"Brulhart L, Waldburger JM, Gabay C (2006) Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 65(7):974\u2013975. \nhttps:\/\/doi.org\/10.1136\/ard.2005.045898","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"4467_CR41","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","volume":"54","author":"H Andersson","year":"2015","unstructured":"Andersson H, Sem M, Lund MB, Aalokken TM, Gunther A, Walle-Hansen R, Garen T, Molberg O (2015) Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford) 54(8):1420\u20131428. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/kev004","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"4467_CR42","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.rmed.2012.01.001","volume":"106","author":"I Marie","year":"2012","unstructured":"Marie I, Dominique S, Janvresse A, Levesque H, Menard JF (2012) Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med 106(4):581\u2013587. \nhttps:\/\/doi.org\/10.1016\/j.rmed.2012.01.001","journal-title":"Respir Med"},{"issue":"3","key":"4467_CR43","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/2049-6958-6-3-183","volume":"6","author":"MC Zappa","year":"2011","unstructured":"Zappa MC, Trequattrini T, Mattioli F, Rivitti R, Vigliarolo R, Marcoccia A, D'Arcangelo G (2011) Rituximab treatment in a case of antisynthetase syndrome with severe interstitial lung disease and acute respiratory failure. Multidiscip Respir Med 6(3):183\u2013188. \nhttps:\/\/doi.org\/10.1186\/2049-6958-6-3-183","journal-title":"Multidiscip Respir Med"},{"issue":"3","key":"4467_CR44","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/08916930600622603","volume":"39","author":"C Torres","year":"2006","unstructured":"Torres C, Belmonte R, Carmona L, Gomez-Reino FJ, Galindo M, Ramos B, Cabello A, Carreira PE (2006) Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 39(3):205\u2013215. \nhttps:\/\/doi.org\/10.1080\/08916930600622603","journal-title":"Autoimmunity"},{"issue":"1","key":"4467_CR45","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s13063-017-2016-2","volume":"18","author":"P Saunders","year":"2017","unstructured":"Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, Babalis D, Renzoni EA, Denton CP, Wells AU, Maher TM (2017) Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials 18(1):275. \nhttps:\/\/doi.org\/10.1186\/s13063-017-2016-2","journal-title":"Trials"},{"issue":"7","key":"4467_CR46","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s10067-018-4122-2","volume":"37","author":"H So","year":"2018","unstructured":"So H, Wong VTL, Lao VWN, Pang HT, Yip RML (2018) Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis. Clin Rheumatol 37(7):1983\u20131989. \nhttps:\/\/doi.org\/10.1007\/s10067-018-4122-2","journal-title":"Clin Rheumatol"},{"issue":"11","key":"4467_CR47","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2169\/internalmedicine.56.7956","volume":"56","author":"K Tokunaga","year":"2017","unstructured":"Tokunaga K, Hagino N (2017) Dermatomyositis with rapidly progressive interstitial lung disease treated with rituximab: a report of 3 cases in Japan. Intern Med 56(11):1399\u20131403. \nhttps:\/\/doi.org\/10.2169\/internalmedicine.56.7956","journal-title":"Intern Med"},{"issue":"6","key":"4467_CR48","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/archderm.143.6.763","volume":"143","author":"L Chung","year":"2007","unstructured":"Chung L, Genovese MC, Fiorentino DF (2007) A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 143(6):763\u2013767. \nhttps:\/\/doi.org\/10.1001\/archderm.143.6.763","journal-title":"Arch Dermatol"},{"issue":"1","key":"4467_CR49","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jaad.2006.05.068","volume":"56","author":"HV Dinh","year":"2007","unstructured":"Dinh HV, McCormack C, Hall S, Prince HM (2007) Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 56(1):148\u2013153. \nhttps:\/\/doi.org\/10.1016\/j.jaad.2006.05.068","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"4467_CR50","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/01.md.0000109755.65914.5e","volume":"83","author":"K Danko","year":"2004","unstructured":"Danko K, Ponyi A, Constantin T, Borgulya G, Szegedi G (2004) Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 83(1):35\u201342. \nhttps:\/\/doi.org\/10.1097\/01.md.0000109755.65914.5e","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"4467_CR51","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jbspin.2007.05.011","volume":"75","author":"Z Touma","year":"2008","unstructured":"Touma Z, Arayssi T, Kibbi L, Masri AF (2008) Successful treatment of cardiac involvement in dermatomyositis with rituximab. Jt Bone Spine 75(3):334\u2013337. \nhttps:\/\/doi.org\/10.1016\/j.jbspin.2007.05.011","journal-title":"Jt Bone Spine"},{"issue":"6","key":"4467_CR52","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3899\/jrheum.171495","volume":"46","author":"O Landon-Cardinal","year":"2019","unstructured":"Landon-Cardinal O, Allenbach Y, Soulages A, Rigolet A, Hervier B, Champtiaux N, Monzani Q, Sole G, Benveniste O (2019) Rituximab in the treatment of refractory anti-HMGCR immune-mediated necrotizing myopathy. J Rheumatol 46(6):623\u2013627. \nhttps:\/\/doi.org\/10.3899\/jrheum.171495","journal-title":"J Rheumatol"},{"issue":"11","key":"4467_CR53","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.nmd.2016.08.013","volume":"26","author":"C Ashton","year":"2016","unstructured":"Ashton C, Junckerstorff R, Bundell C, Hollingsworth P, Needham M (2016) Treatment and outcomes in necrotising autoimmune myopathy: an Australian perspective. Neuromuscul Disord 26(11):734\u2013740. \nhttps:\/\/doi.org\/10.1016\/j.nmd.2016.08.013","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"4467_CR54","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/acr.20219","volume":"62","author":"R Valiyil","year":"2010","unstructured":"Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L (2010) Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) 62(9):1328\u20131334. \nhttps:\/\/doi.org\/10.1002\/acr.20219","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"4467_CR55","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s10067-009-1367-9","volume":"29","author":"S Vordenbaumen","year":"2010","unstructured":"Vordenbaumen S, Neuen-Jacob E, Richter J, Schneider M (2010) Inclusion body myositis in a patient with long standing rheumatoid arthritis treated with anti-TNFalpha and rituximab. Clin Rheumatol 29(5):555\u2013558. \nhttps:\/\/doi.org\/10.1007\/s10067-009-1367-9","journal-title":"Clin Rheumatol"},{"issue":"1\u20132","key":"4467_CR56","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s10354-014-0331-8","volume":"165","author":"E Rath","year":"2015","unstructured":"Rath E, Zwerina J, Oppl B, Nell-Duxneuner V (2015) Efficacy and safety of rituximab in rheumatic diseases. Wien Med Wochenschr 165(1\u20132):28\u201335. \nhttps:\/\/doi.org\/10.1007\/s10354-014-0331-8","journal-title":"Wien Med Wochenschr"},{"issue":"8","key":"4467_CR57","first-page":"1683","volume":"35","author":"JR Lutt","year":"2008","unstructured":"Lutt JR, Pisculli ML, Weinblatt ME, Deodhar A, Winthrop KL (2008) Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis. J Rheumatol 35(8):1683\u20131685","journal-title":"J Rheumatol"},{"issue":"12","key":"4467_CR58","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/rheumatology\/ker305","volume":"50","author":"M Couderc","year":"2011","unstructured":"Couderc M, Gottenberg JE, Mariette X, Hachulla E, Sibilia J, Fain O, Hot A, Dougados M, Euller-Ziegler L, Bourgeois P, Larroche C, Tournadre A, Amoura Z, Mazieres B, Arlet P, De Bandt M, Schaeverbeke T, Soubrier M (2011) Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology (Oxford) 50(12):2283\u20132289. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/ker305","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"4467_CR59","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2169\/internalmedicine.54.2748","volume":"54","author":"M Belhassen-Garcia","year":"2015","unstructured":"Belhassen-Garcia M, Rabano-Gutierrez A, Velasco-Tirado V, Romero-Alegria A, Perez-Garcia ML, Martin-Oterino JA (2015) Atypical progressive multifocal leukoencephalopathy in a patient with antisynthetase syndrome. Intern Med 54(5):519\u2013524. \nhttps:\/\/doi.org\/10.2169\/internalmedicine.54.2748","journal-title":"Intern Med"},{"issue":"3","key":"4467_CR60","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.ejim.2011.01.001","volume":"22","author":"I Marie","year":"2011","unstructured":"Marie I, Guegan-Massardier E, Levesque H (2011) Progressive multifocal leukoencephalopathy in refractory polymyositis treated with rituximab. Eur J Intern Med 22(3):e13\u201314. \nhttps:\/\/doi.org\/10.1016\/j.ejim.2011.01.001","journal-title":"Eur J Intern Med"},{"issue":"6","key":"4467_CR61","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.semarthrit.2017.10.010","volume":"47","author":"A Schiffenbauer","year":"2018","unstructured":"Schiffenbauer A, Garg M, Castro C, Pokrovnichka A, Joe G, Shrader J, Cabalar IV, Faghihi-Kashani S, Harris-Love MO, Plotz PH, Miller FW, Gourley M (2018) A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. Semin Arthritis Rheum 47(6):858\u2013864. \nhttps:\/\/doi.org\/10.1016\/j.semarthrit.2017.10.010","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"4467_CR62","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1007\/s00296-012-2653-4","volume":"33","author":"D Chen","year":"2013","unstructured":"Chen D, Wang XB, Zhou Y, Zhu XC (2013) Efficacy of infliximab in the treatment for dermatomyositis with acute interstitial pneumonia: a study of fourteen cases and literature review. Rheumatol Int 33(10):2455\u20132458. \nhttps:\/\/doi.org\/10.1007\/s00296-012-2653-4","journal-title":"Rheumatol Int"},{"issue":"3\u20134","key":"4467_CR63","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000114036","volume":"59","author":"GJ Hengstman","year":"2008","unstructured":"Hengstman GJ, De Bleecker JL, Feist E, Vissing J, Denton CP, Manoussakis MN, Slott Jensen H, van Engelen BG, van den Hoogen FH (2008) Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 59(3\u20134):159\u2013163. \nhttps:\/\/doi.org\/10.1159\/000114036","journal-title":"Eur Neurol"},{"issue":"12","key":"4467_CR64","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1136\/ard.2007.077974","volume":"67","author":"M Dastmalchi","year":"2008","unstructured":"Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, Elvin K, Crow MK, Nennesmo I, Lundberg IE (2008) A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 67(12):1670\u20131677. \nhttps:\/\/doi.org\/10.1136\/ard.2007.077974","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4467_CR65","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/ana.22477","volume":"70","author":"Muscle Study G","year":"2011","unstructured":"Muscle Study G (2011) A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 70(3):427\u2013436. \nhttps:\/\/doi.org\/10.1002\/ana.22477","journal-title":"Ann Neurol"},{"issue":"9","key":"4467_CR66","first-page":"1802","volume":"33","author":"F Iannone","year":"2006","unstructured":"Iannone F, Scioscia C, Falappone PCF, Covelli M, Lapadula G (2006) Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 33(9):1802\u20131804","journal-title":"J Rheumatol"},{"issue":"9","key":"4467_CR67","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1136\/ard.2005.048744","volume":"65","author":"P Efthimiou","year":"2006","unstructured":"Efthimiou P, Schwartzman S, Kagen LJ (2006) Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 65(9):1233\u20131236. \nhttps:\/\/doi.org\/10.1136\/ard.2005.048744","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4467_CR68","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jbspin.2012.10.012","volume":"80","author":"TC da Silva","year":"2013","unstructured":"da Silva TC, Zon Pretti F, Shinjo SK (2013) Adalimumab in anti-synthetase syndrome. Jt Bone Spine 80(4):432. \nhttps:\/\/doi.org\/10.1016\/j.jbspin.2012.10.012","journal-title":"Jt Bone Spine"},{"issue":"11","key":"4467_CR69","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1007\/s00296-011-2220-4","volume":"32","author":"JK Park","year":"2012","unstructured":"Park JK, Yoo HG, Ahn DS, Jeon HS, Yoo WH (2012) Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab. Rheumatol Int 32(11):3587\u20133590. \nhttps:\/\/doi.org\/10.1007\/s00296-011-2220-4","journal-title":"Rheumatol Int"},{"issue":"4","key":"4467_CR70","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/jcph.1348","volume":"59","author":"J Wronski","year":"2019","unstructured":"Wronski J, Fiedor P (2019) The safety profile of tumor necrosis factor inhibitors in ankylosing spondylitis: are TNF inhibitors safer than we thought? J Clin Pharmacol 59(4):445\u2013462. \nhttps:\/\/doi.org\/10.1002\/jcph.1348","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"4467_CR71","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1007\/s10067-006-0325-z","volume":"26","author":"S Dold","year":"2007","unstructured":"Dold S, Justiniano ME, Marquez J, Espinoza LR (2007) Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin Rheumatol 26(7):1186\u20131188. \nhttps:\/\/doi.org\/10.1007\/s10067-006-0325-z","journal-title":"Clin Rheumatol"},{"key":"4467_CR72","doi-asserted-by":"publisher","first-page":"179180","DOI":"10.1155\/2014\/179180","volume":"2014","author":"AM Brunasso","year":"2014","unstructured":"Brunasso AM, Aberer W, Massone C (2014) New onset of dermatomyositis\/polymyositis during anti-TNF-alpha therapies: a systematic literature review. Sci World J 2014:179180. \nhttps:\/\/doi.org\/10.1155\/2014\/179180","journal-title":"Sci World J"},{"key":"4467_CR73","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04411-8","author":"A Maundrell","year":"2019","unstructured":"Maundrell A, Proudman S, Limaye V (2019) Prevalence of other connective tissue diseases in idiopathic inflammatory myopathies. Rheumatol Int. \nhttps:\/\/doi.org\/10.1007\/s00296-019-04411-8","journal-title":"Rheumatol Int"},{"issue":"3","key":"4467_CR74","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10067-010-1666-1","volume":"30","author":"Y Ishikawa","year":"2011","unstructured":"Ishikawa Y, Yukawa N, Kawabata D, Ohmura K, Fujii T, Usui T, Mimori T (2011) A case of antisynthetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanercept. Clin Rheumatol 30(3):429\u2013432. \nhttps:\/\/doi.org\/10.1007\/s10067-010-1666-1","journal-title":"Clin Rheumatol"},{"issue":"11","key":"4467_CR75","doi-asserted-by":"publisher","first-page":"e0133702","DOI":"10.1371\/journal.pone.0133702","volume":"10","author":"Y Allenbach","year":"2015","unstructured":"Allenbach Y, Guiguet M, Rigolet A, Marie I, Hachulla E, Drouot L, Jouen F, Jacquot S, Mariampillai K, Musset L, Grenier P, Devilliers H, Hij A, Boyer O, Herson S, Benveniste O (2015) Efficacy of Rituximab in refractory inflammatory myopathies associated with anti-synthetase auto-antibodies: an open-label phase II trial. PLoS ONE 10(11):e0133702. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0133702","journal-title":"PLoS ONE"},{"issue":"8","key":"4467_CR76","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/rheumatology\/kep157","volume":"48","author":"M Sem","year":"2009","unstructured":"Sem M, Molberg O, Lund MB, Gran JT (2009) Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford) 48(8):968\u2013971. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/kep157","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"4467_CR77","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1080\/1744666X.2018.1535901","volume":"14","author":"AM Huber","year":"2018","unstructured":"Huber AM (2018) Update on the clinical management of juvenile dermatomyositis. Expert Rev Clin Immunol 14(12):1021\u20131028. \nhttps:\/\/doi.org\/10.1080\/1744666X.2018.1535901","journal-title":"Expert Rev Clin Immunol"},{"issue":"7","key":"4467_CR78","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.3899\/jrheum.101321","volume":"38","author":"B Bader-Meunier","year":"2011","unstructured":"Bader-Meunier B, Decaluwe H, Barnerias C, Gherardi R, Quartier P, Faye A, Guigonis V, Pagnier A, Brochard K, Sibilia J, Gottenberg JE, Bodemer C, Club Rhumatismes et I (2011) Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French autoimmunity and rituximab registry. J Rheumatol 38(7):1436\u20131440. \nhttps:\/\/doi.org\/10.3899\/jrheum.101321","journal-title":"J Rheumatol"},{"issue":"6","key":"4467_CR79","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/rheumatology\/ken074","volume":"47","author":"P Riley","year":"2008","unstructured":"Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA (2008) Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 47(6):877\u2013880. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/ken074","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"4467_CR80","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/acr.22198","volume":"66","author":"KA Rouster-Stevens","year":"2014","unstructured":"Rouster-Stevens KA, Ferguson L, Morgan G, Huang CC, Pachman LM (2014) Pilot study of etanercept in patients with refractory juvenile dermatomyositis. Arthritis Care Res (Hoboken) 66(5):783\u2013787. \nhttps:\/\/doi.org\/10.1002\/acr.22198","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4467_CR81","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jaut.2019.04.016","volume":"101","author":"R Lorenzetti","year":"2019","unstructured":"Lorenzetti R, Janowska I, Smulski CR, Frede N, Henneberger N, Walter L, Schleyer MT, Huppe JM, Staniek J, Salzer U, Venhoff A, Troilo A, Voll RE, Venhoff N, Thiel J, Rizzi M (2019) Abatacept modulates CD80 and CD86 expression and memory formation in human B-cells. J Autoimmun 101:145\u2013152. \nhttps:\/\/doi.org\/10.1016\/j.jaut.2019.04.016","journal-title":"J Autoimmun"},{"issue":"1","key":"4467_CR82","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","volume":"77","author":"A Tjarnlund","year":"2018","unstructured":"Tjarnlund A, Tang Q, Wick C, Dastmalchi M, Mann H, Tomasova Studynkova J, Chura R, Gullick NJ, Salerno R, Ronnelid J, Alexanderson H, Lindroos E, Aggarwal R, Gordon P, Vencovsky J, Lundberg IE (2018) Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann Rheum Dis 77(1):55\u201362. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2017-211751","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4467_CR83","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10067-014-2507-4","volume":"34","author":"AM Kerola","year":"2015","unstructured":"Kerola AM, Kauppi MJ (2015) Abatacept as a successful therapy for myositis-a case-based review. Clin Rheumatol 34(3):609\u2013612. \nhttps:\/\/doi.org\/10.1007\/s10067-014-2507-4","journal-title":"Clin Rheumatol"},{"issue":"4","key":"4467_CR84","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jbspin.2011.03.022","volume":"78","author":"JL Musuruana","year":"2011","unstructured":"Musuruana JL, Cavallasca JA (2011) Abatacept for treatment of refractory polymyositis. Jt Bone Spine 78(4):431\u2013432. \nhttps:\/\/doi.org\/10.1016\/j.jbspin.2011.03.022","journal-title":"Jt Bone Spine"},{"issue":"1","key":"4467_CR85","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.clim.2011.04.006","volume":"142","author":"L Klotz","year":"2012","unstructured":"Klotz L, Meuth SG, Wiendl H (2012) Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab. Clin Immunol 142(1):25\u201330. \nhttps:\/\/doi.org\/10.1016\/j.clim.2011.04.006","journal-title":"Clin Immunol"},{"issue":"1","key":"4467_CR86","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s00415-005-0934-5","volume":"253","author":"AJ Coles","year":"2006","unstructured":"Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, Seaman S, Miller DH, Hale G, Waldmann H, Compston DA (2006) The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253(1):98\u2013108. \nhttps:\/\/doi.org\/10.1007\/s00415-005-0934-5","journal-title":"J Neurol"},{"issue":"3","key":"4467_CR87","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/rheumatology\/keu484","volume":"54","author":"T Ruck","year":"2015","unstructured":"Ruck T, Bittner S, Kuhlmann T, Wiendl H, Meuth SG (2015) Long-term efficacy of alemtuzumab in polymyositis. Rheumatology (Oxford) 54(3):560\u2013562. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/keu484","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"4467_CR88","first-page":"2080","volume":"35","author":"B Thompson","year":"2008","unstructured":"Thompson B, Corris P, Miller JA, Cooper RG, Halsey JP, Isaacs JD (2008) Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. J Rheumatol 35(10):2080\u20132082","journal-title":"J Rheumatol"},{"issue":"Pt 6","key":"4467_CR89","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/brain\/awp104","volume":"132","author":"MC Dalakas","year":"2009","unstructured":"Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, Shrader JA, Levy EW, Dambrosia J, Kampen RL, Bruno DA, Kirk AD (2009) Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 132(Pt 6):1536\u20131544. \nhttps:\/\/doi.org\/10.1093\/brain\/awp104","journal-title":"Brain"},{"issue":"Pt 5","key":"4467_CR90","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1093\/brain\/awp275","volume":"133","author":"SA Greenberg","year":"2010","unstructured":"Greenberg SA (2010) Comment on alemtuzumab and inclusion body myositis. Brain 133(Pt 5):e135. \nhttps:\/\/doi.org\/10.1093\/brain\/awp275\n\n(author reply e136)","journal-title":"Brain"},{"issue":"3","key":"4467_CR91","first-page":"474","volume":"31","author":"N Pipitone","year":"2013","unstructured":"Pipitone N, Salvarani C (2013) CD25 blockade for refractory polymyositis. Clin Exp Rheumatol 31(3):474","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"4467_CR92","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1136\/annrheumdis-2014-205278","volume":"73","author":"J Zou","year":"2014","unstructured":"Zou J, Li T, Huang X, Chen S, Guo Q, Bao C (2014) Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody. Ann Rheum Dis 73(8):1591\u20131593. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2014-205278","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"4467_CR93","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40265-015-0394-x","volume":"75","author":"A Mathian","year":"2015","unstructured":"Mathian A, Hie M, Cohen-Aubart F, Amoura Z (2015) Targeting interferons in systemic lupus erythematosus: current and future prospects. Drugs 75(8):835\u2013846. \nhttps:\/\/doi.org\/10.1007\/s40265-015-0394-x","journal-title":"Drugs"},{"issue":"4","key":"4467_CR94","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/rheumatology\/ket413","volume":"53","author":"X Guo","year":"2014","unstructured":"Guo X, Higgs BW, Rebelatto M, Zhu W, Greth W, Yao Y, Roskos LK, White WI (2014) Suppression of soluble T cell-associated proteins by an anti-interferon-alpha monoclonal antibody in adult patients with dermatomyositis or polymyositis. Rheumatology (Oxford) 53(4):686\u2013695. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/ket413","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"4467_CR95","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40259-013-0076-8","volume":"28","author":"S Dhillon","year":"2014","unstructured":"Dhillon S (2014) Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis. BioDrugs 28(1):75\u2013106. \nhttps:\/\/doi.org\/10.1007\/s40259-013-0076-8","journal-title":"BioDrugs"},{"issue":"3","key":"4467_CR96","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jbspin.2015.03.016","volume":"83","author":"A Beaumel","year":"2016","unstructured":"Beaumel A, Muis-Pistor O, Tebib JG, Coury F (2016) Antisynthetase syndrome treated with tocilizumab. Jt Bone Spine 83(3):361\u2013362. \nhttps:\/\/doi.org\/10.1016\/j.jbspin.2015.03.016","journal-title":"Jt Bone Spine"},{"issue":"12","key":"4467_CR97","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/rheumatology\/kew296","volume":"55","author":"SM Murphy","year":"2016","unstructured":"Murphy SM, Lilleker JB, Helliwell P, Chinoy H (2016) The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome. Rheumatology (Oxford) 55(12):2277\u20132278. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/kew296","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"4467_CR98","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1093\/rheumatology\/keu234","volume":"53","author":"M Kondo","year":"2014","unstructured":"Kondo M, Murakawa Y, Matsumura T, Matsumoto O, Taira M, Moriyama M, Sumita Y, Yamaguchi S (2014) A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis? Rheumatology (Oxford) 53(10):1907\u20131908. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/keu234","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"4467_CR99","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1093\/rheumatology\/ker152","volume":"50","author":"M Narazaki","year":"2011","unstructured":"Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, Tanaka T (2011) Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford) 50(7):1344\u20131346. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/ker152","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04467-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-019-04467-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04467-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:18:36Z","timestamp":1604362716000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-019-04467-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,4]]},"references-count":99,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["4467"],"URL":"https:\/\/doi.org\/10.1007\/s00296-019-04467-6","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,4]]},"assertion":[{"value":"20 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Thomas Khoo declares that he\/she has no conflict of interest. Vidya Limaye declares that he\/she has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}